News and Info

Welcome to the News and Information section of the ECOG-ACRIN Cancer Research Group website. The materials posted in this section are intended to keep constituents informed of the latest news and activities of the organization. The information below includes press releases, announcements, media advisories, and links to news articles.

We welcome inquiries from members of the press regarding the information posted on this website. To place a media inquiry, contact the Office of Communications.


Latest News

February 27, 2023
February 27, 2023
Categories

The TAILORx trial continues to provide reassurance that many women with early breast cancer can safely forego chemotherapy

Do you like it?
Read more
February 23, 2023
February 23, 2023
Categories

A focus on the DREAMseq trial reveals data-driven clinical insights into the selection of first-line treatment options for patients with BRAF-mutated metastatic melanoma

Do you like it?
Read more
February 15, 2023
February 15, 2023
Categories

A participant in the E1910 trial shares her experience in a Penn Medicine feature story with her hematologist, Dr. Selina Luger

Do you like it?
Read more
February 10, 2023
February 10, 2023
Categories

The January/February 2023 News from ECOG-ACRIN blog is now available

Do you like it?
Read more
February 10, 2023
February 10, 2023
Categories

ECOG-ACRIN announces the Remarkable Mentor to Women in Oncology Award (nominations are due March 9)

Do you like it?
Read more
February 9, 2023
February 9, 2023
Categories

The application period is now open for Spring Meeting Attendance Awards for minority trainees

Do you like it?
Read more
February 6, 2023
February 6, 2023
Categories

Ongoing Trial: The INSIGNA clinical trial is testing the timing of immunotherapy alone or with chemotherapy for patients with advanced lung cancer

Do you like it?
Read more
February 1, 2023
February 1, 2023
Categories

Ongoing Trial: The INSPIRE research study is testing a new treatment approach for patients with advanced bladder cancer

Do you like it?
Read more
January 30, 2023
January 30, 2023
Categories

Now Enrolling: The BRIDGE research study is evaluating a new treatment approach for patients with early bladder cancer

Do you like it?
Read more
January 24, 2023
January 24, 2023
Categories

Blinatumomab significantly improves overall survival in newly diagnosed B-ALL patients who are MRD-negative after initial treatment (study E1910)

Do you like it?
Read more
January 5, 2023
January 5, 2023
Categories

The Winter 2023 advocacy blog Considering Clinical Trials is now available

Do you like it?
Read more
December 20, 2022
December 20, 2022
Categories

The November/December 2022 News from ECOG-ACRIN blog is now available

Do you like it?
Read more
December 19, 2022
December 19, 2022
Categories

Blinatumomab Plus Consolidation Chemotherapy Significantly Reduces Risk of Death in MRD-Negative B-Cell ALL

Do you like it?
Read more
December 15, 2022
December 15, 2022
Categories

Study E1910 consolidates the role of blinatumomab in acute lymphoblastic leukemia (ALL)

Do you like it?
Read more
December 14, 2022
December 14, 2022
Categories

Blinatumomab further improves survival among patients with B-ALL and a good prognosis (study E1910)

Do you like it?
Read more
December 13, 2022
December 13, 2022
Categories

Immunotherapy Plus Consolidation Chemo Improves Survival in B Lineage ALL

Do you like it?
Read more
December 13, 2022
December 13, 2022
Categories

HealthDay News informs the public of the 12-year TAILORx results

Do you like it?
Read more
December 13, 2022
December 13, 2022
Categories

Blinatumomab regimen may lead to ā€˜diminishing use of transplantā€™ for B-ALL subgroup (study E1910)

Do you like it?
Read more
December 13, 2022
December 13, 2022
Categories

Press Release: Practice-changing trial results for acute lymphoblastic leukemia (ALL)

Do you like it?
Read more
December 11, 2022
December 11, 2022
Categories

Press Release: A unique clinical trial leads to a dramatic decrease in early deaths from the rare and aggressiveā€”yet highly curableā€”acute promyelocytic leukemia (APL)

Do you like it?
Read more
Load more
News and Info

News

News and Info
Media Contact:
Diane Dragaud, MA
Director of Communications

Send an email

215-789-3631

Categories


Tags

Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML) Advocacy Bladder cancer Blood cancer Brain Cancer Breast cancer Cancer screening Cancer treatment Chemotherapy Clinical trial ComboMATCH Disparities Diversity Gastric cancer Gene testing Genomic testing GI cancer Group meeting Head and neck cancer Health equity Immunotherapy In memory Leadership Leukemia Lung cancer Lymphoma Melanoma Mentorship Multiple myeloma myeloMATCH NCI-MATCH Pancreatic cancer Personalized screening Personalized treatment Precision medicine Precision oncology Prostate cancer Radiology Research results Sarcoma Social determinants of health (SDoH) Survivorship TMIST Treatment trial

 
ECOG-ACRIN Cancer Research Group